Sold as Dapiprazole Hydrochloride. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 16, 2026, FDA lists 2 applications for Dapiprazole Hydrochloride (sold as Dapiprazole Hydrochloride), first approved Dec 31, 1990, with 0 new uses approved and 0 published complete response letters.
| Dec 31, 1990 | Dapiprazole HydrochlorideNDA 19849 ยท New molecular entity | Fera Pharms | 6 | Discontinued |
| May 29, 2019 | Dapiprazole HydrochlorideANDA 204902 | Pharmobedient | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA